Eva Medvedova
About
Eva Medvedova is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Eva Medvedova has authored 47 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 21 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in Eva Medvedova's work include Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (14 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Eva Medvedova is often cited by papers focused on Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (14 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Eva Medvedova collaborates with scholars based in United States, Australia and France. Eva Medvedova's co-authors include Rebecca Silbermann, Parameswaran Hari, Kelly Godby, Saurabh Chhabra, Natalie S. Callander, Luciano J. Costa, Robert F. Cornell, Pamela Hardwick, Aric C. Hall and James Omel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Eva Medvedova
43 papers receiving 722 citations
Peers
Eva Medvedova
James E. Hoffman United States
Ghee Young Kwon South Korea
Stephen R. Zeldenrust United States
Silvia Salmoiraghi Italy
Simona Casarini Italy
M Hasib Sidiqi United States
Jiří Minařík Czechia
Tomáš Pika Czechia
David H. Vesole United States
Shou Ching Tang Canada
Citations per year, relative to Eva Medvedova Eva Medvedova (= 1×)
peers
James E. Hoffman
Countries citing papers authored by Eva Medvedova
Since
Specialization
Citations
This map shows the geographic impact of Eva Medvedova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Medvedova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Medvedova more than expected).
Fields of papers citing papers by Eva Medvedova
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eva Medvedova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Medvedova. The network helps show where Eva Medvedova may publish in the future.
Co-authorship network of co-authors of Eva Medvedova
This figure shows the co-authorship network connecting the top 25 collaborators of Eva Medvedova. A scholar is included among the top collaborators of Eva Medvedova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Medvedova. Eva Medvedova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Masri, Ahmad, et al.. (2025). DIAGNOSTIC PERFORMANCE OF CARDIAC AND WHOLE-BODY 124I-EVUZAMITIDE (AT-01) PET/MRI IN SYSTEMIC AMYLOIDOSIS. Journal of the American College of Cardiology. 85(12). 1183–1183.
2.
Costa, Luciano J., Eva Medvedova, Binod Dhakal, et al.. (2024). Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation. Blood. 144(Supplement 1). 363–363.
3.
Callander, Natalie S., Rebecca Silbermann, Zhubin Gahvari, et al.. (2024). Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial. Blood. 144(Supplement 1). 3365–3365.
4.
Silbermann, Rebecca, Timothy M. Schmidt, Susan Bal, et al.. (2023). Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation. SHILAP Revista de lepidopterología. 4(3). 775–778.
5.
Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2023). Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. The Lancet Haematology. 10(11). e890–e901.
6.
Madan, Sumit, Brea Lipe, Eva Medvedova, et al.. (2023). P-292 Ongoing phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma (MM). Clinical Lymphoma Myeloma & Leukemia. 23. S198–S198.
7.
Costa, Luciano J., Smith Giri, Kelly Godby, et al.. (2023). Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy. Blood. 142(Supplement 1). 2214–2214.
8.
Medvedova, Eva, et al.. (2022). Coexisting sporadic late onset nemaline myopathy and AL amyloid myopathy – incidental or related?. Neuromuscular Disorders. 32(6). 533–538.
9.
Chhabra, Saurabh, Rebecca Silbermann, Bhagirathbhai Dholaria, et al.. (2021). Outcomes of Hematopoietic Progenitor Cells Mobilization and Collection Following Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone Induction in Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy. 27(3). S70–S70.
10.
Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2021). Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 40(25). 2901–2912.
11.
Williamson, Staci, Rebecca Silbermann, Eva Medvedova, et al.. (2021). Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience. Clinical Lymphoma Myeloma & Leukemia. 22(2). 105–112.
12.
Medvedova, Eva, Lynne Strasfeld, Peter Stenzel, & Richard T. Maziarz. (2020). Autopsy among recipients of stem cell transplant for hematologic malignancies in the modern era. Bone Marrow Transplantation. 56(1). 282–284.
13.
Karam, Chafic, et al.. (2020). Diagnosis of paraproteinemic neuropathy: Room for improvement. Journal of the Neurological Sciences. 415. 116902–116902.
14.
Mateos, María‐Victoria, Pieter Sonneveld, Vânia Hungria, et al.. (2019). Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma Myeloma & Leukemia. 20(8). 509–518.
15.
Weisel, Katja, Pieter Sonneveld, María‐Victoria Mateos, et al.. (2019). Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor. Blood. 134(Supplement_1). 3192–3192.
16.
Xu, Xu Steven, Meletios Α. Dimopoulos, Pieter Sonneveld, et al.. (2018). Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Advances in Therapy. 35(11). 1859–1872.
17.
Scott, Emma C., et al.. (2017). Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 18(1). e77–e84.
18.
Shatzel, Joseph J., Richard T. Maziarz, Eva Medvedova, et al.. (2017). Autologous Stem Cell Transplant in the Era of Bortezomib-Based Induction for AL Amyloidosis Results in Improved Hematologic Response Rates: a Single Institution 11 Year Experience. Blood. 130. 4552–4552.
19.
Mateos, María‐Victoria, Jane Estell, Wolney Barreto, et al.. (2016). Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor. Blood. 128(22). 1150–1150.
20.
Ackerman, Kathryn E., Gary S. Skrinar, Eva Medvedova, Madhusmita Misra, & Karen K. Miller. (2011). Estradiol levels predict bone mineral density in male collegiate athletes: a pilot study. Clinical Endocrinology. 76(3). 339–345.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by James E. Hoffman Breakdown of academic impact, for papers by Ghee Young Kwon Breakdown of academic impact, for papers by Stephen R. Zeldenrust Breakdown of academic impact, for papers by Silvia Salmoiraghi Breakdown of academic impact, for papers by Simona Casarini Breakdown of academic impact, for papers by M Hasib Sidiqi Breakdown of academic impact, for papers by Jiří Minařík Breakdown of academic impact, for papers by Tomáš Pika Breakdown of academic impact, for papers by David H. Vesole Breakdown of academic impact, for papers by Shou Ching Tang